INSUBCONTINENT EXCLUSIVE:
Administration, removing a key overhang on the stock
The Nifty Pharma index ended up 0.9 per cent at 8,948.95 and is up 13 per cent from recent lows, reflecting the improving health of the
While pricing pressures in the US continue, analysts believe one can look at select stocks in the mid and large-cap pharma space.
SUN
PHARMACEUTICALCMP (Rs ): 545.65
Last 1-year Return (%): 1.71
Buy/Hold/Sell: 16/13/12
Consensus Target Price (Rs): 523.94
Clearance of Halol
unit by US FDA has fuelled gains in the stock
Gaurav Dua, head of research at BNP Paribas owned-Sharekhan said a lot of negatives are now priced in
There are still pricing pressures in the US but intensity of pressure is easing
Target Price (Rs ): 624.88
Approvals in the developed market and traction from emerging markets (EMs) are leading to positive sentiment in
analyst at ICICI Securities.
ALKEM LABORATORIESCMP (Rs): 2,006.65
Last 1-year Return (%):6.22
Buy/Hold/Sell: 13/2/0
Consensus Target
Price (Rs ): 2,209.38
Saurabh Kumar, Vice President at Motilal Oswal Financial Services said 15-20% return is easily possible from Alkem
1,294.67
Kumar of Motilal Oswal favours the stock because of attractive valuations
1,162.07
Analysts said there is still money to be made in the stock
It had some regulatory issued which are behind us
